CAGE Bio Launches Phase 2b Trial for CGB-500, a Topical JAK Inhibitor for Atopic Dermatitis

CAGE Bio, Inc., a biotechnology company based in SAN CARLOS, CA and FORT WORTH, TX, recently announced a significant advancement in the treatment of atopic dermatitis. The company has initiated a Phase 2b clinical trial for their novel product, CGB-500, a topical JAK inhibitor ointment. This trial is a crucial step forward in developing effective therapies for patients with moderate to severe atopic dermatitis (AD), particularly those with low body surface area involvement.

CGB-500 is formulated using CAGE Bio’s proprietary ionic liquid technology, which allows for direct delivery of medication through the skin. This method aims to combine high therapeutic efficacy with minimal systemic exposure, which is a significant advantage over current treatments. The results from a Phase 2a trial conducted in 2024 were promising, showing that CGB-500 had comparable efficacy to biologic treatments while outperforming existing topicals in minimizing side effects. Specifically, the treatment achieved a success rate of 95% over eight weeks, evidenced by significant improvements in patients' conditions.

The ongoing Phase 2b study involves 180 participants and seeks to optimize dosage regimens while further assessing the safety and effectiveness of CGB-500. The trial represents an important milestone for CAGE Bio by addressing the specific needs of patients who require rapid, effective treatment without the drawbacks associated with systemic therapies. Dr. Justin Ko, a renowned dermatologist from the San Francisco Bay Area, emphasized the potential of CGB-500 to provide patients with targeted relief and mitigate the need for systemic treatments, which often come with undesirable side effects.

CAGE Bio’s CEO, Nitin Joshi, Ph.D., expressed the company's commitment to revolutionizing the treatment approach for atopic dermatitis. With the Phase 2b trial in progress, CAGE Bio is advancing toward its goal of providing highly effective localized therapies that could change the standard of care for immuno-dermatological disorders.

Atopic dermatitis is a prevalent chronic inflammatory skin condition that affects millions worldwide. Patients suffering from localized, moderate to severe symptoms often have limited treatment options. CGB-500 is positioned to fill this therapeutic gap by offering a high-efficacy alternative with reduced systemic exposure risks.

CAGE Bio continues to push the boundaries in developing innovative treatments for immune-mediated dermatological conditions. Their focus on localized therapy using ionic liquid technology not only ensures effective drug delivery to targeted areas but also minimizes systemic exposure, markedly improving patient outcomes.